Onconetix, Inc. (ONCO)
NASDAQ: ONCO · Real-Time Price · USD
4.830
+0.180 (3.87%)
At close: Jun 27, 2025, 4:00 PM
4.800
-0.030 (-0.62%)
After-hours: Jun 27, 2025, 7:59 PM EDT
Onconetix Employees
Onconetix had 5 employees as of December 31, 2024. The number of employees decreased by 7 or -58.33% compared to the previous year.
Employees
5
Change (1Y)
-7
Growth (1Y)
-58.33%
Revenue / Employee
$385,063
Profits / Employee
-$11,498,966
Market Cap
2.52M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 5 | -7 | -58.33% |
| Dec 31, 2023 | 12 | 0 | - |
| Dec 31, 2022 | 12 | 7 | 140.00% |
| Dec 31, 2021 | 5 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
| AbbVie | 55,000 |
ONCO News
- 11 days ago - Onconetix, Inc. Announces Positive Decision by Nasdaq Hearings Panel - GlobeNewsWire
- 16 days ago - Onconetix, Inc. Announces 1-for-85 Reverse Stock Split and Results of the Special Meeting of Stockholders - GlobeNewsWire
- 5 weeks ago - Onconetix, Inc. Announces Receipt of Additional Notice from Nasdaq - GlobeNewsWire
- 5 weeks ago - Onco-Innovations Uplists to Cboe Canada - Business Wire
- 3 months ago - Onconetix Announces Successful Clinical Validation of its Innovative Prostate Cancer Test Proclarix in a Danish cohort - GlobeNewsWire
- 3 months ago - Onconetix Announces New Clinical Data for its Innovative Prostate Cancer Test Proclarix Accepted for Presentation at 2025 European Association of Urology Congress - GlobeNewsWire
- 7 months ago - Onconetix, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q and Subsequent Filing - GlobeNewsWire
- 9 months ago - Virometix appoints Christina Ackermann as Chair and Tim Ramdeen as member of the Board - Business Wire